A global research priority agenda to advance public health responses to fatty liver disease - Inserm - Institut national de la santé et de la recherche médicale
Article Dans Une Revue Journal of Hepatology Année : 2023

A global research priority agenda to advance public health responses to fatty liver disease

Henry E Mark
  • Fonction : Auteur
Alina M Allen
  • Fonction : Auteur
Juan Pablo Arab
Mazen Noureddin
  • Fonction : Auteur
William Alazawi
  • Fonction : Auteur
Naim Alkhouri
Saleh A Alqahtani
  • Fonction : Auteur
Marco Arrese
Ramon Bataller
Thomas Berg
  • Fonction : Auteur
Paul N Brennan
Patrizia Burra
Graciela E Castro-Narro
Helena Cortez-Pinto
Kenneth Cusi
Nikos Dedes
  • Fonction : Auteur
Ajay Duseja
  • Fonction : Auteur
Sven M Francque
Hannes Hagström
  • Fonction : Auteur
Null- K Huang
Dana Ivancovsky Wajcman
  • Fonction : Auteur
Achim Kautz
  • Fonction : Auteur
Christopher J Kopka
  • Fonction : Auteur
Aleksander Krag
Veronica Miller
Philip N Newsome
Mary E Rinella
  • Fonction : Auteur
Diana Romero
Shiv Kumar Sarin
  • Fonction : Auteur
Marcelo Silva
  • Fonction : Auteur
C Wendy Spearman
Emmanuel A Tsochatzis
  • Fonction : Auteur
Luca Valenti
Marcela Villota-Rivas
Shira Zelber-Sagi
Jörn M Schattenberg
  • Fonction : Auteur
Vincent Wai-Sun Wong
Zobair M Younossi
  • Fonction : Auteur

Résumé

Background & aims: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. Methods: Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. Results: The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of 'agree' responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement ('agree' + 'somewhat agree'); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% 'agree'), 13 priorities had <80% 'agree', with greater reliance on 'somewhat agree' to achieve >90% combined agreement. Conclusions: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. Impact and implications: An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat.
Fichier principal
Vignette du fichier
1-s2.0-S0168827823003239-main.pdf (1.17 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

inserm-04546131 , version 1 (15-04-2024)

Licence

Identifiants

Citer

Jeffrey V Lazarus, Henry E Mark, Alina M Allen, Juan Pablo Arab, Patrizia Carrieri, et al.. A global research priority agenda to advance public health responses to fatty liver disease. Journal of Hepatology, 2023, 79, pp.618 - 634. ⟨10.1016/j.jhep.2023.04.035⟩. ⟨inserm-04546131⟩
25 Consultations
53 Téléchargements

Altmetric

Partager

More